Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00439868 · ClinicalTrials.gov registry record · Phase 1

A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure

A Phase 1 study of Depressive Disorder, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
33
Enrollment target
1
Study location

NCT00439868 is a Phase 1 study of Depressive Disorder that has completed, run by GlaxoSmithKline. The registered enrollment target is 33 participants, below the 331-participant average among 47 other Depressive Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00439868, a Phase 1 study of Depressive Disorder, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

This study will be conducted in healthy volunteers to investigate the effect on intraocular pressure of 2 weeks of treatment with 300mg WELLBUTRIN XL/day.

Conditions Studied

Interventions

  • DRUG placebo
  • DRUG WellbutrinXL

Study Locations (1)

Florida

  • GSK Investigational Site - Gainesville

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2007-02-16
Est. Completion 2007-06-08
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT00439868

The ClinicalTrials.gov registry entry for NCT00439868 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 331-participant average among 47 other Depressive Disorder trials with a reported enrollment target (90% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00439868 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT00439868 about?

NCT00439868 is a clinical study titled "A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure". This study will be conducted in healthy volunteers to investigate the effect on intraocular pressure of 2 weeks of treatment with 300mg WELLBUTRIN XL/day.

What is the current status of trial NCT00439868?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2007-02-16. Estimated completion is 2007-06-08.

What conditions does trial NCT00439868 study?

This clinical trial studies the following conditions: Depressive Disorder.

What interventions are being tested in trial NCT00439868?

The interventions under investigation include: placebo (DRUG), WellbutrinXL (DRUG).

Who is sponsoring clinical trial NCT00439868?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00439868 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.